Analysis of Liquidity Ratios
Quarterly Data
Liquidity ratios measure the company ability to meet its short-term obligations.
Liquidity Ratios (Summary)
Illumina Inc., liquidity ratios (quarterly data)
Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).
| Liquidity ratio | Description | The company |
|---|---|---|
| Current ratio | A liquidity ratio calculated as current assets divided by current liabilities. | Illumina Inc. current ratio improved from Q1 2021 to Q2 2021 but then deteriorated significantly from Q2 2021 to Q3 2021. |
| Quick ratio | A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. | Illumina Inc. quick ratio improved from Q1 2021 to Q2 2021 but then deteriorated significantly from Q2 2021 to Q3 2021. |
| Cash ratio | A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. | Illumina Inc. cash ratio improved from Q1 2021 to Q2 2021 but then deteriorated significantly from Q2 2021 to Q3 2021. |
Current Ratio
Illumina Inc., current ratio calculation (quarterly data)
| Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | Dec 31, 2020 | Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | Dec 31, 2016 | Oct 2, 2016 | Jul 3, 2016 | Apr 3, 2016 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Current assets | 2,451) | 5,310) | 5,642) | 4,483) | 4,329) | 4,194) | 4,324) | 4,451) | 4,222) | 4,156) | 4,545) | 4,490) | 4,262) | 3,337) | 3,194) | 2,980) | 2,805) | 2,643) | 2,517) | 2,318) | 2,278) | 2,143) | 2,074) | |||||||
| Current liabilities | 914) | 874) | 1,268) | 1,244) | 1,115) | 1,115) | 1,054) | 665) | 619) | 612) | 1,241) | 1,804) | 1,735) | 1,217) | 1,180) | 746) | 665) | 682) | 721) | 705) | 629) | 582) | 481) | |||||||
| Liquidity Ratio | ||||||||||||||||||||||||||||||
| Current ratio1 | 2.68 | 6.08 | 4.45 | 3.60 | 3.88 | 3.76 | 4.10 | 6.69 | 6.82 | 6.79 | 3.66 | 2.49 | 2.46 | 2.74 | 2.71 | 3.99 | 4.22 | 3.88 | 3.49 | 3.29 | 3.62 | 3.69 | 4.31 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Current Ratio, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 1.01 | 0.91 | 0.83 | 0.84 | 0.95 | 0.86 | 3.14 | 3.18 | 1.15 | 0.89 | 1.04 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 1.64 | 1.31 | 1.66 | 1.81 | 2.28 | 2.18 | 1.59 | 1.44 | 2.89 | 2.89 | 2.77 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 1.47 | 1.54 | 1.56 | 1.58 | 1.67 | 1.47 | 1.66 | 1.60 | 3.83 | 3.88 | 1.93 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 1.48 | 2.26 | 2.05 | 1.86 | 2.08 | 2.20 | 1.32 | 5.19 | 3.43 | 2.32 | 2.18 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 1.30 | 1.15 | 1.42 | 1.40 | 1.36 | 1.22 | 1.11 | 1.16 | 1.17 | 1.13 | 1.12 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 1.37 | 1.36 | 1.37 | 1.40 | 3.25 | 2.33 | 3.04 | 3.10 | 2.96 | 3.76 | 3.62 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 1.34 | 1.39 | 1.28 | 1.21 | 1.48 | 1.25 | 1.31 | 1.26 | 1.26 | 1.33 | 1.44 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 1.31 | 1.31 | 1.02 | 1.02 | 1.30 | 1.32 | 1.11 | 1.24 | 1.26 | 1.21 | 1.37 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 1.39 | 1.37 | 1.48 | 1.35 | 1.40 | 1.42 | 1.03 | 0.88 | 0.90 | 1.47 | 1.54 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 3.71 | 3.57 | 3.12 | 3.63 | 3.89 | 2.12 | 4.21 | 3.67 | 4.03 | 3.88 | 4.58 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 3.19 | 2.78 | 2.53 | 2.13 | 2.93 | 2.62 | 2.32 | 1.92 | 1.80 | 1.49 | 1.69 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Vertex Pharmaceuticals Inc. | 4.62 | 4.61 | 4.39 | 4.33 | 3.72 | 3.72 | 3.54 | 3.61 | 3.44 | 3.74 | 3.78 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).
1 Q3 2021 Calculation
Current ratio = Current assets ÷ Current liabilities
= 2,451 ÷ 914 = 2.68
2 Click competitor name to see calculations.
| Liquidity ratio | Description | The company |
|---|---|---|
| Current ratio | A liquidity ratio calculated as current assets divided by current liabilities. | Illumina Inc. current ratio improved from Q1 2021 to Q2 2021 but then deteriorated significantly from Q2 2021 to Q3 2021. |
Quick Ratio
Illumina Inc., quick ratio calculation (quarterly data)
| Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | Dec 31, 2020 | Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | Dec 31, 2016 | Oct 2, 2016 | Jul 3, 2016 | Apr 3, 2016 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Cash and cash equivalents | 1,080) | 4,196) | 4,433) | 1,810) | 1,761) | 1,770) | 1,991) | 2,042) | 1,815) | 1,943) | 2,270) | 1,144) | 1,346) | 1,344) | 1,560) | 1,225) | 1,354) | 1,219) | 981) | 735) | 795) | 952) | 755) | |||||||
| Short-term investments | 185) | 90) | 197) | 1,662) | 1,563) | 1,498) | 1,341) | 1,372) | 1,351) | 1,230) | 1,345) | 2,368) | 2,043) | 1,168) | 813) | 920) | 687) | 674) | 797) | 824) | 742) | 474) | 588) | |||||||
| Accounts receivable, net | 604) | 540) | 517) | 487) | 464) | 385) | 472) | 573) | 541) | 470) | 457) | 514) | 433) | 395) | 400) | 411) | 383) | 372) | 368) | 381) | 382) | 372) | 403) | |||||||
| Total quick assets | 1,869) | 4,826) | 5,147) | 3,959) | 3,788) | 3,653) | 3,804) | 3,987) | 3,707) | 3,643) | 4,072) | 4,026) | 3,822) | 2,907) | 2,773) | 2,556) | 2,424) | 2,265) | 2,146) | 1,940) | 1,918) | 1,798) | 1,746) | |||||||
| Current liabilities | 914) | 874) | 1,268) | 1,244) | 1,115) | 1,115) | 1,054) | 665) | 619) | 612) | 1,241) | 1,804) | 1,735) | 1,217) | 1,180) | 746) | 665) | 682) | 721) | 705) | 629) | 582) | 481) | |||||||
| Liquidity Ratio | ||||||||||||||||||||||||||||||
| Quick ratio1 | 2.04 | 5.52 | 4.06 | 3.18 | 3.40 | 3.28 | 3.61 | 6.00 | 5.99 | 5.95 | 3.28 | 2.23 | 2.20 | 2.39 | 2.35 | 3.43 | 3.65 | 3.32 | 2.98 | 2.75 | 3.05 | 3.09 | 3.63 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Quick Ratio, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 0.75 | 0.65 | 0.61 | 0.60 | 0.68 | 0.58 | 2.88 | 2.91 | 0.92 | 0.64 | 0.78 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 1.19 | 0.86 | 1.16 | 1.30 | 1.65 | 1.60 | 1.10 | 1.01 | 2.28 | 2.41 | 2.37 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 1.16 | 1.16 | 1.25 | 1.28 | 1.43 | 1.26 | 1.38 | 1.26 | 3.63 | 3.61 | 1.64 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 0.93 | 1.67 | 1.51 | 1.36 | 1.52 | 1.59 | 0.92 | 4.68 | 2.99 | 1.78 | 1.58 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 0.79 | 0.67 | 0.83 | 0.85 | 0.79 | 0.68 | 0.64 | 0.68 | 0.66 | 0.67 | 0.65 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 1.01 | 1.05 | 0.99 | 1.08 | 2.93 | 2.09 | 2.78 | 2.86 | 2.74 | 3.41 | 3.32 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 1.03 | 1.04 | 0.97 | 0.91 | 1.17 | 0.92 | 0.98 | 0.94 | 0.93 | 0.95 | 1.01 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 0.78 | 0.75 | 0.58 | 0.58 | 0.77 | 0.84 | 0.66 | 0.78 | 0.80 | 0.75 | 0.88 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 0.99 | 0.91 | 0.88 | 0.78 | 0.93 | 0.98 | 0.60 | 0.50 | 0.50 | 0.71 | 0.72 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 3.03 | 2.92 | 2.39 | 2.86 | 3.02 | 1.61 | 3.38 | 2.81 | 3.14 | 2.99 | 3.66 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 2.37 | 1.92 | 1.70 | 1.63 | 2.16 | 1.83 | 1.48 | 1.19 | 0.97 | 0.85 | 0.89 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Vertex Pharmaceuticals Inc. | 4.21 | 4.16 | 4.06 | 4.02 | 3.46 | 3.47 | 3.27 | 3.33 | 3.20 | 3.51 | 3.54 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).
1 Q3 2021 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= 1,869 ÷ 914 = 2.04
2 Click competitor name to see calculations.
| Liquidity ratio | Description | The company |
|---|---|---|
| Quick ratio | A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. | Illumina Inc. quick ratio improved from Q1 2021 to Q2 2021 but then deteriorated significantly from Q2 2021 to Q3 2021. |
Cash Ratio
Illumina Inc., cash ratio calculation (quarterly data)
| Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | Dec 31, 2020 | Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | Dec 31, 2016 | Oct 2, 2016 | Jul 3, 2016 | Apr 3, 2016 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Cash and cash equivalents | 1,080) | 4,196) | 4,433) | 1,810) | 1,761) | 1,770) | 1,991) | 2,042) | 1,815) | 1,943) | 2,270) | 1,144) | 1,346) | 1,344) | 1,560) | 1,225) | 1,354) | 1,219) | 981) | 735) | 795) | 952) | 755) | |||||||
| Short-term investments | 185) | 90) | 197) | 1,662) | 1,563) | 1,498) | 1,341) | 1,372) | 1,351) | 1,230) | 1,345) | 2,368) | 2,043) | 1,168) | 813) | 920) | 687) | 674) | 797) | 824) | 742) | 474) | 588) | |||||||
| Total cash assets | 1,265) | 4,286) | 4,630) | 3,472) | 3,324) | 3,268) | 3,332) | 3,414) | 3,166) | 3,173) | 3,615) | 3,512) | 3,389) | 2,512) | 2,373) | 2,145) | 2,041) | 1,893) | 1,778) | 1,559) | 1,536) | 1,425) | 1,343) | |||||||
| Current liabilities | 914) | 874) | 1,268) | 1,244) | 1,115) | 1,115) | 1,054) | 665) | 619) | 612) | 1,241) | 1,804) | 1,735) | 1,217) | 1,180) | 746) | 665) | 682) | 721) | 705) | 629) | 582) | 481) | |||||||
| Liquidity Ratio | ||||||||||||||||||||||||||||||
| Cash ratio1 | 1.38 | 4.90 | 3.65 | 2.79 | 2.98 | 2.93 | 3.16 | 5.13 | 5.11 | 5.18 | 2.91 | 1.95 | 1.95 | 2.06 | 2.01 | 2.88 | 3.07 | 2.78 | 2.47 | 2.21 | 2.44 | 2.45 | 2.79 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Cash Ratio, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 0.43 | 0.30 | 0.31 | 0.30 | 0.33 | 0.25 | 2.50 | 2.56 | 0.61 | 0.32 | 0.38 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 0.87 | 0.55 | 0.82 | 0.91 | 1.24 | 1.09 | 0.68 | 0.69 | 1.94 | 2.05 | 2.07 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 0.73 | 0.68 | 0.75 | 0.83 | 1.03 | 0.92 | 0.95 | 0.84 | 3.10 | 3.02 | 0.99 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 0.35 | 1.07 | 0.93 | 0.82 | 0.94 | 0.99 | 0.52 | 4.04 | 2.40 | 1.08 | 0.84 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 0.28 | 0.22 | 0.26 | 0.29 | 0.30 | 0.20 | 0.14 | 0.21 | 0.15 | 0.20 | 0.19 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 0.56 | 0.64 | 0.58 | 0.65 | 2.52 | 1.79 | 2.34 | 2.50 | 2.39 | 3.03 | 2.97 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 0.70 | 0.65 | 0.60 | 0.59 | 0.79 | 0.52 | 0.54 | 0.54 | 0.51 | 0.49 | 0.53 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 0.42 | 0.39 | 0.26 | 0.30 | 0.36 | 0.50 | 0.32 | 0.47 | 0.39 | 0.35 | 0.47 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 0.71 | 0.61 | 0.51 | 0.47 | 0.64 | 0.70 | 0.31 | 0.26 | 0.25 | 0.40 | 0.39 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 1.56 | 1.05 | 1.09 | 1.33 | 1.29 | 0.85 | 1.95 | 1.53 | 1.63 | 1.56 | 2.14 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 1.55 | 1.01 | 0.80 | 1.00 | 1.21 | 0.97 | 0.54 | 0.39 | 0.22 | 0.30 | 0.19 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Vertex Pharmaceuticals Inc. | 3.64 | 3.65 | 3.56 | 3.55 | 3.07 | 3.03 | 2.72 | 2.85 | 2.88 | 3.14 | 3.14 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).
1 Q3 2021 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= 1,265 ÷ 914 = 1.38
2 Click competitor name to see calculations.
| Liquidity ratio | Description | The company |
|---|---|---|
| Cash ratio | A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. | Illumina Inc. cash ratio improved from Q1 2021 to Q2 2021 but then deteriorated significantly from Q2 2021 to Q3 2021. |